Manufacturer of Controlled Substances; Notice of Application, 71558 [E5-6609]
Download as PDF
<![CDATA[
71558
Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices
States International Trade Commission
(Commission) determines, pursuant to
section 751(b) of the Tariff Act of 1930
(19 U.S.C. 1675d(b)) (the Act), that
revocation of the antidumping duty
orders covering certain frozen
warmwater shrimp and prawns from
India and Thailand would be likely to
lead to continuation or recurrence of
material injury to an industry in the
United States. Certain frozen warmwater
shrimp and prawns from India and
Thailand are provided for in
subheadings 0306.13.00 and 1605.20.10
of the Harmonized Tariff Schedule of
the United States.
Background
On December 17, 2004, the
Department of Commerce determined
that imports of certain frozen and
canned warmwater shrimp and prawns
from India and Thailand are being sold
in the United States at less than fair
value (LTFV) within the meaning of
section 731 of the Act (19 U.S.C. 1673)
(69 FR 76916, 76918, December 23,
2004); and on January 6, 2005 the
Commission determined, pursuant to
section 735(b)(1) of the Act (19 U.S.C.
1673d(b)(1)), that an industry in the
United States was materially injured by
reason of imports of such LTFV
merchandise. Accordingly, Commerce
ordered that antidumping duties be
imposed on such imports (70 FR 5143,
February 1, 2005).
On January 6, 2005, when the
Commission conducted its vote in the
original investigations, it stated that it
was concerned about the possible
impact of the December 26, 2004,
tsunami on the shrimp industries of
India and Thailand. The tsunami
occurred prior to the closing of the
record in the original investigations on
December 27, 2004. At the time the
record closed, however, factual
information as to any impact of the
tsunami on the ability of producers in
India or Thailand to produce and export
shrimp was not available. On February
8, 2005, the Commission published a
Federal Register notice (70 FR 6728)
inviting comments from the public on
whether changed circumstances exist
sufficient to warrant the institution of
changed circumstances reviews of the
Commission’s affirmative
determinations concerning certain
frozen warmwater shrimp and prawns
from India and Thailand.
The Commission instituted the
subject investigations (investigation
Nos. 751–TA–28–29), effective May 5,
2005, after having reviewed the
comments it received in response to that
request, and having determined that it
had received information which showed
VerDate Aug<31>2005
20:13 Nov 28, 2005
Jkt 208001
changed circumstances sufficient to
warrant instituting review investigations
and that there was good cause for
instituting such review investigations
within two years after publication of the
orders. Notice of the scheduling of the
Commission’s investigations and of a
public hearing to be held in connection
therewith was given by posting copies
of the notice in the Office of the
Secretary, U.S. International Trade
Commission, Washington, DC, and by
publishing the notice in the Federal
Register of May 5, 2005 (70 FR 23884).
The hearing was held in Washington,
DC, on September 14, 2005, and all
persons who requested the opportunity
were permitted to appear in person or
by counsel.
The Commission transmitted its
determinations in these investigations to
the Secretary of Commerce on
November 21, 2005. The views of the
Commission are contained in USITC
Publication 3813 (November 2005),
entitled Certain Frozen Warmwater
Shrimp and Prawns from India and
Thailand: Investigation Nos. 751–TA–
28–29.
Issued: November 21, 2005.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E5–6593 Filed 11–28–05; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on March 3,
2005, American Radiolabeled
Chemicals, Inc., 101 Arc Drive, St.
Louis, Missouri 63146, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedules I and II:
Drug
Schedule
Gamma
hydroxybutyric
acid
(2010).
Dimethyltryptamine (7435) ...........
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lysergic acid diethylamide (7315).
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
I
I
I
II
II
II
II
II
II
II
II
Drug
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ecgonine (9180) ...........................
Meperidine (9230) ........................
Metazocine (9240) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Schedule
II
II
II
II
II
II
II
II
The company plans to manufacture in
bulk, small quantities of the listed
controlled substances as radiolabeled
compounds.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Acting Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, Washington, DC 20537,
Attention: DEA Federal Register
Representative, Liaison and Policy
Section (ODL); or any being sent via
express mail should be sent to DEA
Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401
Jefferson Davis Highway, Alexandria,
Virginia 22301; and must be filed no
later than January 30, 2006.
Joseph T. Rannazzisi,
Acting Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration.
[FR Doc. E5–6609 Filed 11–28–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on May 6,
2005, Chemic Laboratories, Inc., 480
Neponset Street, Building 7C, Canton,
Massachusetts 02021, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture
small quantities of a cocaine derivative
for distribution to its customers for the
purpose of research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 70, Number 228 (Tuesday, November 29, 2005)]
[Notices]
[Page 71558]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-6609]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 3, 2005, American
Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146,
made application by renewal to the Drug Enforcement Administration
(DEA) for registration as a bulk manufacturer of the basic classes of
controlled substances listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma hydroxybutyric acid (2010). I
Dimethyltryptamine (7435).................. I
Dihydromorphine (9145)..................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Lysergic acid diethylamide (7315). II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ecgonine (9180)............................ II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
The company plans to manufacture in bulk, small quantities of the
listed controlled substances as radiolabeled compounds.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Acting Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than January 30, 2006.
Joseph T. Rannazzisi,
Acting Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration.
[FR Doc. E5-6609 Filed 11-28-05; 8:45 am]
BILLING CODE 4410-09-P
